1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Date not available
Admin
News Article

Ascentage Pharma Receives Clearance from US FDA to Proceed with Phase III Clinical Trial for Lisaftoclax (APG-2575)

Ascentage Pharma has received clearance from the US Food and Drug Administration (FDA) to initiate a global Phase III study for their novel Bcl-2 inhibitor, lisaftoclax (APG-2575), in the treatment of patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) previously treated with a Bruton's tyrosine kinase inhibitor (BTKi).

The Phase III study, named APG2575CG301, is a significant step in the development of lisaftoclax as a potential treatment option for CLL/SLL patients who have relapsed or developed resistance to existing therapies, including BTKis.

The study is designed as a randomised-controlled trial and will be conducted across multiple centres globally. Its main focus will be to evaluate the efficacy and safety of combining lisaftoclax with a BTKi in this specific patient population.

Lisaftoclax is an orally administered small-molecule Bcl-2 selective inhibitor. Bcl-2 is a protein that plays a crucial role in regulating apoptosis, the process of programmed cell death. In cancer cells, overexpression of Bcl-2 can disrupt normal apoptosis and contribute to uncontrolled cell growth and survival. By targeting Bcl-2, lisaftoclax aims to restore the normal apoptotic process, leading to the elimination of cancer cells.

CLL/SLL is a type of leukaemia that predominantly affects adults. It is characterised by the abnormal accumulation of mature lymphocytes in the blood, bone marrow, and lymph nodes. Although current treatment options, such as immunotherapies, chemotherapies, and BTKis, can initially lead to positive responses in patients, relapse and drug resistance often emerge as significant challenges in managing the disease.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!